Lee Shwamm, MD


Stroke Prevention and Atrial Fibrillation Management, Thoughts From STROKE-AF Study: Lee Shwamm, MD

The professor of neurology at Harvard Medical School spoke at the 2023 ISC Conference about highlights from the STROKE-AF study after a 3-year follow-up. [WATCH TIME: 5 minutes]

Allitia DiBernardo, MD


Importance of Evaluating Real-World Populations in MS: Allitia DiBernardo, MD

The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.

Mary Anne Meskis


Advice for Managing Dravet Syndrome and LGS

Mary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.

Andreas Forsland


Combining Brain-Computer Interface with Augmented Reality for Neurodegenerative Diseases: Andreas Forsland

The chief executive officer of Cognixion talked about the Cognixion ONE Axon, a wireless, wearable brain-computer interface that combines EEG technology with an augmented reality headset for patients with neurodegenerative diseases. [WATCH TIME: 4 minutes]

Katherine Podraza, MD, PhD


Retinal Vasculature Changes in Migraine With Aura: Katherine Podraza, MD, PhD

The headache specialist at the Hartford Healthcare Headache Center discussed findings from a study that revealed altered retinal vasculature in individuals with migraine with aura, indicating potential retinal biomarkers for disease progression. [WATCH TIME: 4 minutes]

Crystal Sada


Both Sides Now: The Before and After of CIDP’s Diagnostic Journey

Crystal, a patient living with chronic inflammatory demyelinating polyneuropathy and one of the faces of the Shining Through CIDP awareness campaign, discussed the diagnostic challenges associated with the rare disease.

Mark I. Boulos, MD, MSc, FRCP, CSCN


2024 Clinical Preview for Emerging Trends in Sleep Disorders: Mark I. Boulos, MD, BSc, FRCP, CSCN, MSc

The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, shared his thoughts on potential therapies and expanding care options for sleep disorders in 2024. [WATCH TIME: 5 minutes]

Noah Stansfield


Where Are We: Development of Gene and Cell Approaches for Parkinson Disease

According to recent studies and the latest insights provided by experts, early developments in gene and cell therapies show promise for patients living with Parkinson disease, but challenges remain.

Jihan A. Grant, MD


Search for Targeted Therapies for Primary Headaches Beyond Migraine: Jihan A. Grant, MD

The director of headache medicine at The Mount Sinai Hospital talked about the often-overlooked realm of primary headaches beyond migraines as well as the importance of developing targeted treatments and increasing understanding of their pathophysiology. [WATCH TIME: 7 minutes]

Katherine Turk, MD


Improving Diagnosis, Screening Patients More Efficiently in Alzheimer Disease: Katherine Turk, MD

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Aaron Miller, MD, FAAN


Practice Pearls for Management of NMOSD

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

Bradley McDaniels, PhD, CRC


Tools for Cultivating Meaning This Holiday Season

What excites you? What awakens your sense of purpose? What gives your life meaning? Bradley McDaniels, PhD, CRC, explores the importance of meaning in one's life.

Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN


AUPN Leadership Minute Episode 28: Leadership to Effect Change

Episode 28 of the AUPN Leadership Minute features Donald S. Higgins, MD, of the VHA; and Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN, of University of Oxford. [WATCH TIME: 5 minutes]

Annette Okai, MD, FAAN


Getting Up to Speed on the Evolving Landscape of Multiple Sclerosis: Annette Okai, MD

The medical director of the North Texas Institute of Neurology and Headache offered an overview of the State of the Science Summit that was held on July 21, 2022, with a variety of expert clinicians in MS care. [WATCH TIME: 3 minutes]

Fiona Gupta, MD


Dyskinesia: Importance of Giving Patients More Good “On- Time" In Parkinson’s Disease

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

Yuebing Li, MD, PhD


Efficacy and Safety of Weekly Subcutaneous Efgartigimod for Myasthenia Gravis: Yuebing Li, MD, PhD

The neuromuscular neurologist at the Cleveland Clinic discussed findings from an analysis presented at AANEM 2023 that investigated the safety and efficacy of subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 5 minutes]

Garth T. Whiteside, PhD


Sleep Disturbances and Recovering From Alcohol Use Disorder: Garth T. Whiteside, PhD

The head of preclinical development at Imbrium Therapeutics provided an overview of positive safe and efficacy findings from the phase 2 study investigating sunobinop. [WATCH TIME: 4 minutes]

Eric Leuthardt, MD


Streamlining Stroke Rehab Systems in Common Clinical Care: Eric Leuthardt, MD

The founder and chief scientific officer of Neurolutions discussed complexities within the system to integrate new stroke rehab devices.

Brian Nagle, MD


Promising Disease-Modifying Therapies in Parkinson Disease

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

Sube Banerjee, MD, MSc, MBA, FRCPysch


Reimaging the Approach to Treating Alzheimer Agitation: Sube Banerjee, MD, MSc, MBA, FRCPsych

The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the way to attack Alzheimer agitation and why drug solutions often fall short. [WATCH TIME: 3 minutes]

Vikram Bhise, MD


Talking Transitional Readiness for Teens With Multiple Sclerosis: Vikram Bhise, MD

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]

Alexandra Nelson, MD, PhD


AUPN Leadership Minute Episode 39: Supporting K Awardees

Episode 39 of the AUPN Leadership Minute features Donald S. Higgins Jr, MD, of Veterans Health Administration, Albany Medical College; and Alexandra Nelson, MD, PhD, of the University of California San Francisco. [WATCH TIME: 5 minutes]

Sharon L. Rogers, PhD


The Complexities of Alzheimer Disease Treatment and Diagnosis in Clinical Trials: Sharon L. Rogers, PhD

The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. [WATCH TIME: 6 minutes]

Mony de Leon, EdD


Insights Into Nasal Pathways for Brain Protein Sampling and Treatment Delivery: Mony de Leon, EdD

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]

Jess Holguin, OTD, OT/L


Ongoing Challenges for Neuromuscular and Movement Occupational Therapy: Jess Holguin, OTD, OT/L

Commenting on recent advances and persistent challenges for these patients, the associate professor of clinical occupational therapy at USC Keck Hospital spoke on the need to increase equity and access to care. [WATCH TIME: 6 minutes]

Ashkan Shoamanesh, MD


Secondary Analyses of ANNEXA-I Trial Assessing Andexanet Alfa in Intracranial Hemorrhage: Ashkan Shoamanesh, MD

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]

Paula Barreras, MD


Overcoming Language Barriers During the Diagnostic Process of Rare Neuroimmune Disorders: Paula Barreras, MD

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center detailed the difficulties with discussing neuroimmune disorders with newly diagnosed patients, including those who may not speak English. [WATCH TIME: 3 minutes]

Jennifer Martin, PhD


Cognitive Behavioral Therapy vs. Pharmacological Treatments for Insomnia: Jennifer Martin, PhD

The AASM board of directors' member and professor of medicine at UCLA discussed the benefits of CBT-I and its efficacy compared to pharmacological treatments.

Jill Morris, PhD


Global Impacts of Rare Disease Day for Patients With Neurologic Disorders: Jill Morris, PhD

The program director in the division of Neuroscience at the National Institute of Neurological Disorders and Stroke provided context on the importance of Rare Disease Day and strides made over the years. [WATCH TIME: 5 minutes]

Kristin Guilliams, MD, MSCI


Importance of Identifying Etiology in Pediatric Stroke: Kristin Guilliams, MD, MSCI

The associate professor at Washington University School of Medicine provided commentary on the state of care for pediatric stroke, and the challenges with identifying the most likely etiology. [WATCH 3 minutes]

© 2024 MJH Life Sciences

All rights reserved.